Clinical Trial Update: Safety and Efficacy Study of HYTOP® in the Treatment of Focal Chondral Defects. [NA]

View source ↗

Summary

The update reports the completion of a safety and efficacy study evaluating HYTOP® for focal chondral defects of the knee. Sponsored by TRB Chemedica AG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Chondral Defect of the Knee

Drugs mentioned

• HYTOP®

Snippet

Sponsor: TRB Chemedica AG | Conditions: Focal Chondral Defect in Femoro-tibial Compartment of the Knee Joint | NA | Status: COMPLETED